Adeno-associated virus phage or AAVP, is a hybrid vector platform developed by combining the targeting capability of bacteriophage and the sustained gene expression of adeno-associated virus. Bacteriophage has been used clinically for decades as an anti-microbial agent. Bacteriophage is a virus that infects bacteria, but cannot infect human cells. AAVP has successfully developed a version of bacteriophage that can infect, but not replicate, in specific human cells. That specificity can be tailored to a cell of choice, such as a tumor cell or tumor associated cell. Normally, if a bacteriophage infects a human cell, no gene expression takes place. However, AAVP’s hybrid AAVP can express a gene product in a human cell based on the fact that it carries the gene expression machinery of an adeno-associated virus, but not the adeno-associated virus itself thus avoiding the limitations well known to adeno-associated virus including the need for a helper virus and robust immunogenicity limiting clinical efficacy. The result is a platform that can be tailored to target any human cell and express exclusively in that cell, any gene of interest. The company has generated AAVP that infect a variety of cell types and express a variety of gene products, both for therapy and for imaging. AAVP’s lead therapeutic, RGD-AAVP-TNF, is designed to selectively infect tumor associated blood vessels and express TNF exclusively in the tumor vascular bed resulting in tumor necrosis. The company has validated this tumor targeting and selective gene expression, as well as therapeutic efficacy and absence of toxicity, in small and large animals. In fact, RGD-AAVP-TNF has been administered in the context of a clinical trial in dogs demonstrating safety and anti-tumor activity. AAVP has generated substantial pre-clinical data on stability, dosing and lack of toxicity and is targeting an IND filing for a first in human clinical trial in patients with advanced stage malignancies.